Year: 2010
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: BACKGROUND: Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus. METHODS: In seven African countries, women infected with HIV-1 whose CD4+ T-cell counts were below 200 per cubic millimeter and who either had or had not taken single-dose nevirapine at least 6 months before enrollment were randomly assigned to receive antiretroviral therapy with tenofovir–emtricitabine plus nevirapine or tenofovir-emtricitabine plus lopinavir boosted by a low dose of ritonavir. The primary end point was the time to confirmed virologic failure or death. RESULTS: A total of 241 women who had been exposed to single-dose nevirapine began the study treatments (121 received nevirapine and 120 received ritonavir-boosted lopinavir). Significantly more women in the nevirapine group reached the primary end point than in the ritonavir-boosted lopinavir group (26% vs. 8%) (adjusted P=0.001). Virologic failure occurred in 37 (28 in the nevirapine group and 9 in the ritonavir-boosted lopinavir group), and 5 died without prior virologic failure (4 in the nevirapine group and 1 in the ritonavir-boosted lopinavir group). The group differences appeared to decrease as the interval between single-dose nevirapine exposure and the start of antiretroviral therapy increased. Retrospective bulk sequencing of baseline plasma samples showed nevirapine resistance in 33 of 239 women tested (14%). Among 500 women without prior exposure to single-dose nevirapine, 34 of 249 in the nevirapine group (14%) and 36 of 251 in the ritonavir-boosted lopinavir group (14%) had virologic failure or died. CONCLUSIONS: In women with prior exposure to peripartum single-dose nevirapine (but not in those without prior exposure), ritonavir-boosted lopinavir plus tenofovir–emtricitabine was superior to nevirapine plus tenofovir–emtricitabine for initial antiretroviral therapy. (Funded by the National Institute of Allergy and Infectious Diseases and the National Research Center; ClinicalTrials.gov number, NCT00089505.).
Source: New England Journal of Medicine
Authors: S. Lockman, M.D. Hughes, J. McIntyre, Y. Zheng, T. Chipato, F. Conradie, F. Sawe, A. Asmelash, M.C. Hosseinipour, L. Mohapi, E. Stringer, R. Mngqibisa, A. Siika, D. Atwine, J. Hakim, D. Shaffer, C. Kanyama, K. Wools-Kaloustian, R.A. Salata, E. Hogg, B. Alston-Smith, A. Walawander, E. Purcelle-Smith, S. Eshleman, J. Rooney, S. Rahim, J.W. Mellors, R.T. Schooley, J.S. Currier
Institutions: Brigham and Women's Hospital, Harvard University, Anova Health Institute, University of Zimbabwe, University of the Witwatersrand, Kenya Medical Research Institute, Botswana Harvard AIDS Institute Partnership, Kamuzu Central Hospital, Chris Hani Baragwanath Hospital, Centre for Infectious Disease Research in Zambia, University of Alabama at Birmingham, University of KwaZulu-Natal, Moi University, Joint Clinical Research Centre, Indiana University School of Medicine, Case Western Reserve University, AIDS Clinical Trials Group, Social and Scientific Systems (United States), National Institutes of Health, Frontier Science & Technology Research Foundation, Inc., Johns Hopkins University, Johns Hopkins Medicine, Gilead Sciences (United States), Abbott (United States), UPMC Presbyterian, University of Pittsburgh Medical Center, University of California San Diego, University of California, Los Angeles
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G115468880, G2873213803, Optimizing Antiretroviral Therapy in HIV , AIDS Clinical Trials Group Network, Statistical and Data Management Center for the AIDS Clinical Trials Group, G7638877966, G9000130697, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)
OpenAlex ID: W2118784602
